Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer.

OBJECTIVE The aim of this study was to determine midkine (MK) and pleiotrophin (PTN) expression in cervical cancer. METHODS Prospective study in tertiary teaching hospital. Normal and cancerous cervical tissues were obtained from healthy women (n = 19) and from patients with cervical cancer (n = 42). The expressions of MK and PTN mRNA and protein were examined by quantitative competitive PCR and by immunohistochemistry. MK and PTN mRNA and protein expressions were examined with respect to tumor stage and size. RESULTS The expressions of midkine and pleiotrophin mRNA in cervical cancer were higher than those in the normal cervix (MK, 175.59 +/- 63.3 vs 1.00 +/- 0.18 fmol, respectively; PTN, 3.18 +/- 1.25 vs. 0.86 +/- 0.12 fmol, respectively, P < 0.05), and their expressions were not correlated with cervical cancer stage or size of the tumor. The expressions of MK and PTN protein in cancerous tissue were higher than those in the normal cervix (P < 0.05). Moreover, the protein expression of MK, but not of PTN, correlated with tumor stage and size. The expressions of MK and PTN were not correlated with vascular density. CONCLUSIONS Our results suggest that increased midkine mRNA and protein expressions are associated with the carcinogenesis of cervical cancer.

[1]  T. Deuel,et al.  Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Jaye,et al.  Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. , 1994, Growth factors.

[3]  M. Wick,et al.  Midkine and pleiotrophin expression in normal and malignant breast tissue , 1994, Cancer.

[4]  T. Muramatsu,et al.  Expression of Midkine and Pleiotropin in Ovarian Tumors , 1997, Obstetrics and gynecology.

[5]  S. Donnini,et al.  An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. , 1997, Cancer research.

[6]  S. Takao,et al.  Increased Midkine Gene Expression in Human Gastrointestinal Cancers , 1995, Japanese journal of cancer research : Gann.

[7]  M. Noda,et al.  Levels of expression of pleiotrophin and protein tyrosine phosphatase zeta are decreased in human colorectal cancers. , 1998, Cancer letters.

[8]  A. Harris,et al.  The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. , 1996, Cancer research.

[9]  M. Noda,et al.  Haptotactic Migration Induced by Midkine , 2001, The Journal of Biological Chemistry.

[10]  Seung Cheol Kim,et al.  Concentration of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in the serum of patients with cervical cancer: prediction of response. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[11]  Michael Cross,et al.  Growth factors in development, transformation, and tumorigenesis , 1991, Cell.

[12]  T. Deuel,et al.  Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. , 1999, Current opinion in hematology.

[13]  A. Wellstein,et al.  Pleiotrophin and midkine in normal development and tumor biology. , 1995, Critical reviews in oncogenesis.

[14]  M. Matsuyama,et al.  Expression of midkine in the early stage of carcinogenesis in human colorectal cancer , 1999, British Journal of Cancer.

[15]  M. Watson,et al.  Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. , 1990, Science.

[16]  C. Lowenstein,et al.  Midkine Induces Tumor Cell Proliferation and Binds to a High Affinity Signaling Receptor Associated with JAK Tyrosine Kinases* , 1998, The Journal of Biological Chemistry.

[17]  T. Shintani,et al.  6B4 Proteoglycan/Phosphacan, an Extracellular Variant of Receptor-like Protein-tyrosine Phosphatase ζ/RPTPβ, Binds Pleiotrophin/Heparin-binding Growth-associated Molecule (HB-GAM)* , 1996, The Journal of Biological Chemistry.

[18]  T. Muramatsu,et al.  Midkine induces the transformation of NIH3T3 cells. , 1997, British Journal of Cancer.

[19]  M. Noda,et al.  Pleiotrophin signals increased tyrosine phosphorylation of β-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase β/ζ , 2000 .

[20]  Y. Wen,et al.  Interleukin-1β Regulates Urokinase Plasminogen Activator (u-PA), u-PA Receptor, Soluble u-PA Receptor, and Plasminogen Activator Inhibitor-1 Messenger Ribonucleic Acid Expression in Cultured Human Endometrial Stromal Cells1 , 2001 .

[21]  S. Natsugoe,et al.  Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas. , 1998, British Journal of Cancer.

[22]  A. Wellstein,et al.  Signal Transduction Pathways Involved in the Mitogenic Activity of Pleiotrophin , 1997, Journal of Biological Chemistry.

[23]  D. Wen,et al.  Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin* , 2001, The Journal of Biological Chemistry.

[24]  H. Chung,et al.  Expression and Tyrosine Phosphorylation of E-Cadherin, β- and γ-Catenin, and Epidermal Growth Factor Receptor in Cervical Cancer Cells☆ , 2001 .

[25]  H. Rauvala,et al.  Molecular cloning of the 18-kDa growth-associated protein of developing brain. , 1990, The Journal of biological chemistry.

[26]  A. Nakagawara,et al.  A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. , 1993, Cancer research.